CAMBRIDGE, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the ...

Vericel (NASDAQ:VCEL) held its 2026 annual meeting of shareholders on April 29 in a virtual format, with Chairman Dr. Robert ...

“The Company delivered another quarter of solid financial and business results in the second quarter, with significant revenue growth and even higher profitability growth and margin expansion as well ...

5 analysts have shared their evaluations of Vericel (NASDAQ:VCEL) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table provides a quick overview of ...

Vericel Corporation (VCEL) came out with quarterly earnings of $0.45 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.38 per share a year ago. These figures are ...

It is hard to get excited after looking at Vericel's (NASDAQ:VCEL) recent performance, when its stock has declined 18% over the past month. But if you pay close attention, you might find that its key ...

Vericel continues to see strong revenue growth stemming from their two commercial products, Epicel and MACI. Future sales growth prospects for MACI remain strong and will fuel the stock higher. Their ...

Last month, Vericel reported record second quarter revenues – the fifth consecutive time they have topped previous numbers. The Cambridge Massachusetts-based cell therapy company has two products on ...

Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying before the Q4 market crash that the stock market is overvalued due to a low interest rate environment that leads to ...

Full-Year 2023 Total Revenue Growth of 20% to $197.5 Million, with Adjusted EBITDA Growth of 40% Fourth Quarter Total Revenue Growth of 23% to $65.0 Million, with Adjusted EBITDA Growth of 50% Fourth ...